Den daglige serumeksponering for nilotinib med 400 mg to gange dagligt ved steady state var 35% højere end med 800 mg en gang dagligt.
Daily serum exposure to nilotinib with 400 mg twice-daily dosing at steady state was 35% higher than with 800 mg once-daily dosing.